Cathy Eng, MD
Cann CG et al. Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Frontiers Oncol 2023;13:1176950. Abstract
Nakamura Y et al. Predicting recurrence using a tumor-uninformed ctDNA assay detecting MRD in patients with resected stage II or III colorectal cancer: Subset analysis from the GALAXY study in CIRCULATE-Japan. ASCO 2023;Abstract 21.
Strickler JH et al. HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS. ASCO 2023;Abstract 3528.
Strickler JH et al. Real-world treatment patterns in patients with HER2-amplified metastatic colorectal cancer: A clinical-genomic database study. J Natl Compr Canc Netw 2023;21(8):805-12. Abstract
Strickler JH et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study. Lancet Oncol 2023;24(5):496-508. Abstract
Watanabe J et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer. JAMA 2023;329(15):1271-82. Abstract
Christopher Lieu, MD
Cercek A et al. Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. ASCO 2023;Abstract TPS3639.
Cercek A et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363-76. Abstract
Chalabi M et al. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. ESMO 2022;Abstract LBA7.
Dasari A et al. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. ASCO 2023;Abstract 3522.
Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract
Malla M et al. Using circulating tumor DNA in colorectal cancer: Current and evolving practices. J Clin Oncol 2022;40(24):2846-57. Abstract
Oki E et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. ASCO 2023;Abstract 3521.
Sahin IH et al. Neoadjuvant immune checkpoint inhibitor therapy for patients with microsatellite instability-high colorectal cancer: Shedding light on the future. JCO Oncol Pract 2023;19(5):251-9. Abstract
Shirasu H et al. A randomized, double-blind, phase III study comparing trifluridine/tipiracil hydrochloride therapy versus placebo in resected colorectal cancer patients who are positive for blood circulating tumor DNA after standard adjuvant therapy (EPOC 1905): ALTAIR trial in CIRCULATE-Japan (trial in progress). Gastrointestinal Cancers Symposium 2022;Abstract TPS215.
Tie J et al. Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. ASCO 2022;Abstract LBA100.
Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261-72. Abstract
Verschoor YL et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. ASCO 2022;Abstract 3511.
Tanios Bekaii-Saab, MD
Ciombor KK et al. BRAF-mutated advanced colorectal cancer: A rapidly changing therapeutic landscape. J Clin Oncol 2022;40(24):2706-15. Abstract
Kopetz S et al. BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). ASCO 2023;Abstract TPS3627.
Morris MJ et al. Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. ASCO 2022;Abstract TPS5104.
Tabernero et al. Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial. ESMO 2022;Abstract 614P.
Andrea Cercek, MD
Andre T et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Gastrointestinal Cancers Symposium 2024;Abstract LBA768.
Le DT et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: Final analysis of KEYNOTE-164. Eur J Cancer 2023;186:185-95. Abstract
Lenz H-J et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142. Gastrointestinal Cancers Symposium 2024;Abstract 97.
Overman MJ et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. ASCO 2022;Abstract 3510.
John Strickler, MD
Bekaii-Saab TS et al. MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. ASCO 2023;Abstract TPS3631.
Desai J et al. Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation. Cancer Res 2023;83(8_Supplement): CT029. Abstract
Fakih MG et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23(1):115-24. Abstract
Kuboki et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: A phase 1b trial. Nat Med 2024;30(1):265-70. Abstract
Mullard A. The KRAS crowd targets its next cancer mutations. Nat Rev Drug Discov 2023:22(3);167-71. Abstract
Pietrantonio F et al. Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study. ESMO 2023;Abstract LBA10.
Raghav KPS et al. Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: Circulating tumor DNA analysis of the CALGB/SWOG-80405 trial (Alliance). J Clin Oncol 2023;41(3):472-8. Abstract
Raghav KPS et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. ASCO 2023;Abstract 3501.
Ryan MB et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep 2022:39(12);1-14. Abstract
Strickler JH et al. HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS. ASCO 2023;Abstract 3528.
Strickler JH et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study. Lancet Oncol 2023;24(5):496-508. Abstract
Yaeger R et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2023;388(1):44-54. Abstract
Yoshino T et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023;14(1):3332. Abstract